These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29109117)

  • 1. Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.
    Delker DA; Wood AC; Snow AK; Samadder NJ; Samowitz WS; Affolter KE; Boucher KM; Pappas LM; Stijleman IJ; Kanth P; Byrne KR; Burt RW; Bernard PS; Neklason DW
    Cancer Prev Res (Phila); 2018 Jan; 11(1):4-15. PubMed ID: 29109117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
    Samadder NJ; Neklason DW; Boucher KM; Byrne KR; Kanth P; Samowitz W; Jones D; Tavtigian SV; Done MW; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Davis R; Topham MK; Lynch P; Strait E; McKinnon W; Burt RW; Kuwada SK
    JAMA; 2016 Mar 22-29; 315(12):1266-75. PubMed ID: 27002448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Predicators of Duodenal Familial Adenomatous Polyposis Chemoprevention: Do Chemopreventive Drugs Hit Their Presumed Molecular Targets?
    Shureiqi I
    Cancer Prev Res (Phila); 2018 Jan; 11(1):1-3. PubMed ID: 29263155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
    Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
    JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
    Samadder NJ; Foster N; McMurray RP; Burke CA; Stoffel E; Kanth P; Das R; Cruz-Correa M; Vilar E; Mankaney G; Buttar N; Thirumurthi S; Turgeon DK; Sossenheimer M; Westover M; Richmond E; Umar A; Della'Zanna G; Rodriguez LM; Szabo E; Zahrieh D; Limburg PJ
    Gut; 2023 Feb; 72(2):256-263. PubMed ID: 35636921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
    Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Expression Changes Accompanying the Duodenal Adenoma-Carcinoma Sequence in Familial Adenomatous Polyposis.
    Thiruvengadam SS; OʼMalley M; LaGuardia L; Lopez R; Wang Z; Shadrach BL; Chen Y; Li C; Veigl ML; Barnholtz-Sloan JS; Pai RK; Church JM; Kalady MF; Walsh RM; Burke CA
    Clin Transl Gastroenterol; 2019 Jun; 10(6):e00053. PubMed ID: 31211760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
    Brosens LA; Iacobuzio-Donahue CA; Keller JJ; Hustinx SR; Carvalho R; Morsink FH; Hylind LM; Offerhaus GJ; Giardiello FM; Goggins M
    Clin Cancer Res; 2005 Jun; 11(11):4090-6. PubMed ID: 15930344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP).
    Ulusan AM; Rajendran P; Dashwood WM; Yavuz OF; Kapoor S; Gustafson TA; Savage MI; Brown PH; Sei S; Mohammed A; Vilar E; Dashwood RH
    Cancer Prev Res (Phila); 2021 Mar; 14(3):325-336. PubMed ID: 33277315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.
    Gross ND; Bauman JE; Gooding WE; Denq W; Thomas SM; Wang L; Chiosea S; Hood BL; Flint MS; Sun M; Conrads TP; Ferris RL; Johnson JT; Kim S; Argiris A; Wirth L; Nikiforova MN; Siegfried JM; Grandis JR
    Clin Cancer Res; 2014 Jun; 20(12):3289-98. PubMed ID: 24727329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variables affecting penetrance of gastric and duodenal phenotype in familial adenomatous polyposis patients.
    Sample DC; Samadder NJ; Pappas LM; Boucher KM; Samowitz WS; Berry T; Westover M; Nathan D; Kanth P; Byrne KR; Burt RW; Neklason DW
    BMC Gastroenterol; 2018 Jul; 18(1):115. PubMed ID: 30012100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulindac plus erlotinib for familial adenomatous polyposis.
    Baker H
    Lancet Oncol; 2016 May; 17(5):e183. PubMed ID: 27051970
    [No Abstract]   [Full Text] [Related]  

  • 14. Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and
    Thomas LE; Hurley JJ; Meuser E; Jose S; Ashelford KE; Mort M; Idziaszczyk S; Maynard J; Brito HL; Harry M; Walters A; Raja M; Walton SJ; Dolwani S; Williams GT; Morgan M; Moorghen M; Clark SK; Sampson JR
    Clin Cancer Res; 2017 Nov; 23(21):6721-6732. PubMed ID: 28790112
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis.
    Nugent KP; Farmer KC; Spigelman AD; Williams CB; Phillips RK
    Br J Surg; 1993 Dec; 80(12):1618-9. PubMed ID: 8298943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial turnover in duodenal familial adenomatous polyposis: A possible role for estrogen receptors?
    Di Leo A; Nesi G; Principi M; Piscitelli D; Girardi B; Pricci M; Losurdo G; Iannone A; Ierardi E; Tonelli F
    World J Gastroenterol; 2016 Mar; 22(11):3202-11. PubMed ID: 27003997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprevention in familial adenomatous polyposis: past, present and future.
    Kemp Bohan PM; Mankaney G; Vreeland TJ; Chick RC; Hale DF; Cindass JL; Hickerson AT; Ensley DC; Sohn V; Clifton GT; Peoples GE; Burke CA
    Fam Cancer; 2021 Jan; 20(1):23-33. PubMed ID: 32507936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months.
    Winde G; Schmid KW; Schlegel W; Fischer R; Osswald H; Bünte H
    Dis Colon Rectum; 1995 Aug; 38(8):813-30. PubMed ID: 7634976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of chromoendoscopy for surveillance of the duodenum in patients with MUTYH-associated polyposis and familial adenomatous polyposis.
    Hurley JJ; Thomas LE; Walton SJ; Thomas-Gibson S; Haycock A; Suzuki N; Mort M; Williams G; Morgan M; Clark SK; Sampson JR; Dolwani S
    Gastrointest Endosc; 2018 Oct; 88(4):665-673. PubMed ID: 29702101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial.
    van Heumen BW; Roelofs HM; Vink-Börger ME; Dekker E; Mathus-Vliegen EM; Dees J; Koornstra JJ; Langers AM; Nagtegaal ID; Kampman E; Peters WH; Nagengast FM
    Orphanet J Rare Dis; 2013 Aug; 8():118. PubMed ID: 23919274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.